



## State of Louisiana

Louisiana Department of Health Office of Public Health

CONFIDEN	HAL HEPATITIS B AN	D HEPAIIIIS	CKEPOR	TING WC	PRKSHEET	
Patient Name:		MRI	VI·		_ SS#:	
Last	First	Middle	··			
Address:				Tel:	( )	
City:	Parish:		St	tate:	,	
Sex (at birth):	Date of Birth:	Country of Birth:		Date o	of death:/	
☐ Male ☐ Female	/ / USA □ Othe		er: State of death:			
Gender (if applicable):				o tato		
☐ Male to female transgender				11.27		
☐ Female to male transgender	□ No	□ White				
1	□ Unknown	□ Asian wn □ Black/African				
Other: DIAGNOSTIC TESTING						
Collection Date Ordering Site						
Diagnostic Tests			(mm/dd/yyyy) (if other than reporting facility)			
HBV DIAGNOSTIC TESTING				,,,,,		
☐ IgM antibody to hepatitis B core antigen [IgM anti-HBc]			1	1		
☐ Positive ☐ Negative			,	1		
☐ Hepatitis B surface antigen [HBsAg] ☐ Positive ☐ Negative			1	1		
☐ Nucleic Acid Testing for hepatitis B [Hep B NAT]						
□ Positive/Detected □ Negative/Not Detected			/	1		
IU/mLLog IU/mL						
☐ Hepatitis B "e" antigen [HBeAg]			1	1		
☐ Positive ☐ Negative			,			
☐ Other (specify):			1	1		
HCV DIAGNOSTIC TESTING						
☐ Antibody to HCV [anti-HCV] ☐ Positive ☐ Negative anti-HCV signal to cut-off			1	1		
☐ HCV RNA/PCR Qualitative						
☐ Positive/Detected ☐ Negative/Not Detected			/	1		
☐ HCV RNA/PCR Quantitative			,	1		
IU/mLLog IU/mL			1	1		
☐ HCV Genotype			1	1		
☐ Other (specify):			/	1		
CLINICAL INFORMATION						
☐ Is patient experiencing symptoms of	consistent with hepatitis?   Ye	s 🗆 No 🗆 Unk	Has patient red	ceived medi	cation for hepatitis being reported?	
If yes, onset date/			☐ Yes ☐ No ☐ Unknown  Date of earliest use://  Please list known hepatitis medications and duration:			
☐ At diagnosis, was the patient						
Hospitalized for hepatitis?   Yes  No  Unk  Le patient suggestive property   Yes  No  Unk						
Is patient currently pregnant? ☐ Yes ☐ No ☐ Unk  If yes, estimated date of delivery://				Р	lease mail or fax to:	
Was patient vaccinated for Hepatitis B within last 30 days? ☐ Yes ☐ No ☐ Unk					ATTN: Hepatitis Surveillance	
If yes, date of most recent vaccination:/_/					TD/HIV/Hepatitis Program	
REPORTING INFORMATION Louisiana Office of Public Heal					ouisiana Office of Public Health	
Reporting Facility: Date:				New Orleans, I Δ 70160		
Address: State: Zip:					h: (504) 568-7474	
Reporting Physician:Phone: ( )					ax: (504) 568-8384	
Person Completing Form:	Phone	e: (       )			, ,	

## To Our Providers:

This worksheet was developed to assist with timely reporting of Hepatitis B and C cases by the diagnosing and/or managing physician, by collecting the most critical information requested by the Centers for Disease Control and Prevention (CDC). In some cases, staff of the STD/HIV/Hepatitis Program (SHHP), under the Department of Health Office of Public Health, may need to contact the facility for additional information not included on this worksheet. If a provider prefers to complete the CDC Viral Hepatitis Case Report Form him- or herself, copies may be obtained from the SHHP contact listed at the bottom of the form. Case reports may also be made by phone to the SHHP contact, or SHHP staff can complete the required forms on site via a chart review. Please include as much information as is available; partial or approximate dates are acceptable for historical information.

When present the signs and symptoms of acute hepatitis infection include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain, and jaundice.

A hepatitis B blood panel should be used to screen for HBV and includes hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (Anti-HBs) and hepatitis B core antibody (anti-HBc). All positive results and additional testing to monitor persons with hepatitis B infection should be reported.

HCV antibody testing with reflex to HCV RNA polymerase chain reaction testing is recommended for initial hepatitis C screening. Among persons at risk for reinfection after previous spontaneous or treatment-related viral clearance, HCV-RNA testing is recommended because a positive HCV-antibody is expected. All results and additional testing to monitor persons with hepatitis C infection should be reported.

Guidance on Hepatitis B and Hepatitis C can be found through the American Association of Liver Diseases (aasld.org) and CDC (cdc.gov/hepatitis).

Reporting Requirements: Louisiana's Public Health Sanitary Code (Title 51, Part II, Chapter 1) requires that any physician practicing medicine in the State of Louisiana who attends or examines a person with Hepatitis B (acute, carriage in pregnancy or perinatal infection) or Hepatitis C (acute or perinatal infection) must report the case by the end of the next business day after the existence of a case, suspected case, or a positive laboratory result is known (Class B). Chronic Hepatitis C infection is reportable within 5 business days (Class C). Positive laboratory results for Hepatitis B and all laboratory results (both positive and negative) for Hepatitis C are reportable. Other health care providers, laboratories, and other entities have similar reporting requirements.

HIPAA Guidelines Related to Disclosures for Public Health Activities: The Privacy Rule permits covered entities to disclose protected health information, without authorization, to public health authorities who are legally authorized to receive such reports for the purpose of preventing or controlling disease, injury, or disability. See 45 CFR 164.512(b)(1)(i).